Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Sentynl Therapeutics, Mereo BioPharma partner on rare lung disease drug alvelestat, $475M deal
Licensing deal, rare disease, small molecule, milestone payments, royalties - Read more

Hemogenyx Pharmaceuticals, Cellin Technologies collaborate on CAR-T therapy manufacturing and clinical implementation in Estonia
Manufacturing agreement, oncology, cell therapy, CAR-T, revenue sharing - Read more

Science 2 Sales is the outbound engine for companies selling into biotech & pharma. We handle the market intelligence, prospect scoring, email sequences, LinkedIn outreach, and cold calling - so your sales team inherits a full calendar of qualified meetings.

Built by biopharma BD & sales reps, exclusively for biopharma commercial teams. It’s the platform and service we wish we had years ago.

Learn more and book a free strategy call on our website.

MoonLake Immunotherapeutics reports Ph3 data for (sonelokimab) targeting interleukin-17A/F in psoriatic arthritis
Antibody, autoimmune, nanobody, psoriatic arthritis, IL-17A/F inhibitor - Read more

Bios Life emerges from stealth with $25M, partners with Tempus to personalize cancer screening and surveillance
AI diagnostics, oncology, strategic, major transaction - Read more

Infinimmune raises $75M Series A, backed by Regeneron Ventures for eczema antibody development
Antibody, autoimmune, eczema, preclinical, platform technology - Read more

Vaderis Therapeutics raises $152M Series B to advance AKT-targeting HHT treatment
Rare disease, small molecule, AKT inhibitor, clinical-stage - Read more

Epicrispr Biotechnologies raises $90M Series C to advance epigenetic editing treatment for FSHD
Epigenetic editing, CRISPR, rare disease, neuromuscular, clinical-stage - Read more

Sona Nanotech closes oversubscribed $2.5M private placement, advancing photothermal cancer therapy
Oncology, gold nanoparticles, photothermal therapy, preclinical, solid tumors - Read more

Aureka Biotechnologies raises $100M Series B to advance AI-driven drug discovery efforts
AI/ML platform, drug discovery, antibody, protein design, platform-enabled - Read more

Remedium Bio raises $10M initial Series A, advancing gene therapy platform for protein therapeutics
Gene therapy, preclinical, protein therapeutics, platform technology - Read more

Bristol Myers Squibb commits $2.3B to build Houston manufacturing campus, creating 2,500 jobs
Multi-modal manufacturing, small molecule, biologics, antibody-drug conjugate, operational, major transaction - Read more

Jazz Pharmaceuticals to acquire Actio Biosciences for up to $1.3B, expanding rare epilepsy pipeline
Small molecule, rare epilepsy, strategic, major transaction - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

FDA rejects ITM Isotope Technologies' (177Lu-edotreotide) for gastroenteropancreatic neuroendocrine tumors over manufacturing concerns
Radiopharmaceutical, cancer, small molecule, neuroendocrine tumors, lutetium-177, manufacturing - Read more

Aura Biosciences lays off 20% of staff, refocuses pipeline on ocular oncology under new CEO
Virus-like drug conjugate, ocular oncology, cost reduction, operational, strategic - Read more

Trump signs executive order to reduce childhood vaccine schedule from 17 to 11 recommended shots
Vaccines, infectious disease, regulatory, public health policy - Read more

Scholar Rock drops Novo Nordisk's troubled Catalent plant in apitegromab FDA refiling for SMA
Monoclonal antibody, rare disease, regulatory, operational - Read more

Fresenius Kabi recalls one lot of Tyenne tocilizumab-aazg 400mg vials nationwide over glass particle contamination
Monoclonal antibody, autoimmune, operational, safety recall - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here